Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is determine Time-to-Progression with elotuzumab plus lenalidomide
when elotuzumab is added to multiple myeloma participants with serologic relapse/progression
while receiving lenalidomide maintenance for each study arm.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute